PhRMA Presses Case For Dumping 340B Orphan Drug Rule

Law360, New York (April 14, 2015, 4:52 PM ET) -- Pharmaceutical Research and Manufacturers of America is once again pushing a D.C. federal court to nix a U.S. Department of Health and Human Services interpretative rule on discounts for orphan drugs under the 340B program, arguing that the rule has legally binding consequences that are ripe for judicial review.



PhRMA said in a brief Friday that HHS has already threatened some noncompliant drugmakers with administrative action that could lead to monetary penalties and the exclusion from the 340B program or even from Medicaid entirely, placing the...

To view the full article, register now.